# Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences
Ticker: ALLO
Company: Allogene Therapeutics
Source: Allogene Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.allogene.com
## Summary

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three

## Article Body
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three
## Recent Company News
- 2026-06-25 13:46 EST — [Allogene Therapeutics Announces Planned CEO Succession](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13-2026) — Source: Allogene Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)